Patents Examined by Golam M M Shameem
  • Heterocyclic compounds and uses thereof
    Patent number: 9388183
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: July 12, 2016
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson, Alfredo C. Castro, Catherine A. Evans, Daniel A. Snyder
  • Secondary amines as therapeutic agents
    Patent number: 9388153
    Abstract: Compounds such as those represented by Formulas 1-6 can be used in topical liquids, creams, or other dosage forms such as solids, for reducing intraocular pressure, treating glaucoma, growing hair, or other medical uses.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: July 12, 2016
    Assignee: ALLERGAN, INC.
    Inventors: Vinh X. Ngo, David W. Old
  • Acrylic compound having tetraoxaspiro backbone for radiation curing compositions
    Patent number: 9388194
    Abstract: Disclosed is a process for obtaining an acrylic compound having a tertaoxaspiro backbone and at least one acrylic unsaturation. Said compound is in embodiments an acrylate, a methacrylate or a crotonate of an alkoxylated, such as an ethoxylated, a propoxylated and/or a butoxylated 2,4,8,10-tetraoxaspiro[5.5]undecane3,9-dialkanol.
    Type: Grant
    Filed: January 15, 2014
    Date of Patent: July 12, 2016
    Assignee: PERSTORP AB
    Inventors: David James, Linda Zellner
  • Intermediate of Ertapenem, a composition comprising the same and preparation methods thereof
    Patent number: 9388184
    Abstract: Intermediates of Ertapenem of formula 2a wherein Np represents (I) or (II), and P1 and P2 represent carboxyl protecting groups, and their preparation methods. Compound 2a prepared by the present methods in solid form is amorphous. The present invention also relates to a composition comprising at least 95% of the intermediate of Ertapenem of formula 2a.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: July 12, 2016
    Assignee: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD.
    Inventors: Ying Shi, Kun Li, Zan Xie, Xuebin Zhao, Jian Lv, Xiuqin Yu
  • Synthetic route for the preparation of ?-aminobutyryl substituted 5,6,7,8-tetrahydro[1,4]diazolo[4,3-alpha ]pyrazin-7-yl compounds
    Patent number: 9388188
    Abstract: The present invention relates to a process for preparing ?-aminobutyryl substituted 5,6,7,8-tetrahydro[1,4]diazolo[4,3-?]pyrazin-7-yl compounds.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: July 12, 2016
    Assignee: Lek Pharmaceuticals d.d.
    Inventors: Stefan Starcevic, Peter Mrak, Gregor Kopitar
  • Forms of vilazodone and processes for the preparation thereof
    Patent number: 9382233
    Abstract: Vilazodone hydrochloride benzyl alcohol solvates are provided as well as processes for the preparation thereof.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: July 5, 2016
    Assignee: Apotex Inc.
    Inventors: Gamini Weeratunga, Murali Kondamreddy, Allan W. Rey, Cameron L. McPhail, Yajun Zhao
  • Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
    Patent number: 9382254
    Abstract: The present invention discloses compounds according to Formula I: wherein R1, R2, R3, L, and the subscript m are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions, and methods of treatment using the same, for the treatment of cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: July 5, 2016
    Assignee: GALAPAGOS NV
    Inventors: Ann De Blieck, Tom Roger Lisette De Munck, Caroline Martine Andrée Marie Joannesse, Hans Kelgtermans, Oscar Mammoliti, Christel Jeanne Marie Menet, Giovanni Alessandro Tricarico, Steven Emiel Van der Plas
  • Linagliptin solid dispersion
    Patent number: 9381199
    Abstract: The present invention provides a novel amorphous solid dispersion of linagliptin in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it.
    Type: Grant
    Filed: July 8, 2013
    Date of Patent: July 5, 2016
    Assignee: Hetero Research Foundation
    Inventors: Bandi Parthasaradhi Reddy, Kura Rathnakar Reddy, Dasari Muralidhara Reddy, Kesireddy Subash Chander Reddy, Bandi Vamsi Krishna
  • Methods for making oxetan-3-ylmethanamines
    Patent number: 9376409
    Abstract: This invention relates to methods for making oxetan-3-ylmethanamines having the formula (I) wherein R1? and R2? are as defined herein. The methods of the invention provide the compounds of formula (I) in high yields and under conditions amenable for large-scale commercial production.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: June 28, 2016
    Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Magnus Carl Arne Eriksson, Suresh R. Kapadia, Jonathan Timothy Reeves, Xingzhong Zeng
  • Diphenylmethane derivatives as SGLT2 inhibitors
    Patent number: 9371303
    Abstract: A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: June 21, 2016
    Assignee: GREEN CROSS CORPORATION
    Inventors: Soongyu Choi, Kwang-Seop Song, Suk Ho Lee, Min Ju Kim, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, So Ok Park, Hyunku Kang, Myung Eun Jung, Kinam Lee, Hyun Jung Kim, Jun Sung Lee, Min Woo Lee, Mi-Soon Kim, Dong Ho Hong, Misuk Kang
  • Tyrosinase inhibitors
    Patent number: 9364405
    Abstract: The compositions and methods of described herein comprise novel ingredients effective to reduce unwanted pigmentation, such as skin discoloration, freckles, age spots, liver spots, sun damage, tans, pigmented acne marks, scars, pigmented birthmarks, hyperpigmentation, post-inflammatory hyperpigmentation, post-injury hyperpigmentation, melasma, cholasma, after-burn scar, nail stain, yellowing of skin, dark circles under eyes, and the like. The composition may include additional ingredients accordingly for a colored cosmetic, moisturizer, cleanser, toner, and the like.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: June 14, 2016
    Assignee: Avon Products, Inc.
    Inventors: Hong Hu, Sunghan Yim, Uma Santhanam, John W. Lyga
  • Process for the preparation of dasatinib and its intermediates
    Patent number: 9365526
    Abstract: The present invention relates to processes for the preparation of dasatinib and its intermediates.
    Type: Grant
    Filed: December 31, 2013
    Date of Patent: June 14, 2016
    Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Jagdev Singh Jaryal, Munish Kapoor, Swargam Sathyanarayana, Rajesh Kumar Thaper, Mohan Prasad
  • Process for preparing episulfide compounds
    Patent number: 9359324
    Abstract: Provided is a method for producing an episulfide compound, the method including a step of thiating epoxy groups of (B) an epoxy compound by a reaction with (C) a thiating agent in the presence of (A) a polyhydric hydroxyl compound having two or more hydroxyl groups.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: June 7, 2016
    Assignee: Asahi Kasei Chemicals Corporation
    Inventors: Akitake Nakamura, Takeshi Endo
  • Lipoyl compounds and methods for treating ischemic injury
    Patent number: 9359325
    Abstract: The present invention relates, in various embodiments, to a compound represented by Structural Formula (I), pharmaceutically acceptable salts or prodrugs thereof, and compositions comprising said compounds, or pharmaceutically acceptable salts or prodrugs thereof. Methods of using compounds of Structural Formulas (I) and (Ia) or compositions comprising compounds of Structural Formulas (I) and (Ia), or pharmaceutically acceptable salts or prodrugs thereof, to treat ischemia or ischemia-reperfusion injury are also disclosed.
    Type: Grant
    Filed: August 11, 2014
    Date of Patent: June 7, 2016
    Assignee: Ischemix LLC
    Inventors: Alexander B. Baguisi, Reinier Beeuwkes, Ralph Casale, Steven A. Kates, Alan S. Lader
  • Process for the synthesis of 2,5-furandicarboxylic acid
    Patent number: 9359318
    Abstract: Process for the synthesis of 2,5-furandicarboxylic acid through the oxidation of -hydroxymethylfurfural in a flow of oxygenor a compound containing oxygen, catalyzed by a supported catalyst containing a metal of the platinum group, carried out in aqueous solution in which the pH is maintained higher than 7 and lower than 12 through the addition of a weak base.
    Type: Grant
    Filed: August 4, 2011
    Date of Patent: June 7, 2016
    Assignee: Novamont S.p.A.
    Inventors: Giampietro Borsotti, Francesca Digioia
  • Substituted xanthines and methods of use thereof
    Patent number: 9359359
    Abstract: Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 7, 2016
    Assignee: HYDRA BIOSCIENCES, INC.
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • Complex targeting hepatitis B virus
    Patent number: 9353105
    Abstract: A compound medicine for treating acute and chronic hepatitis B, includes a polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex, which has functions of directly killing HBV and destroying replication template of HBV. Auxiliary formulas thereof include high-purity oxymatrine and glycyrrhizin sulfate. The oxymatrine has an effect of anti-HBV, and is capable of treating acute and chronic hepatitis B, regulating immune system and increasing leukocyte. Serving as a main hepatocyte membrane protective agent, the glycyrrhizin sulfate has not only an effect of anti-inflammation, but also it is capable of regulating immune system and protecting hepatocyte. The compound medicine has no toxicity or side effect.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: May 31, 2016
    Assignee: Shanghai Ai Qi Ecological Technology Co., Ltd.
    Inventors: Gong Chen, Kunyuan Song
  • Methods for preparing anti-viral nucleotide analogs
    Patent number: 9346841
    Abstract: Methods for isolating 9-{(R)-2-[((S)-{[(S)-1-(isopropoxycarbonyl)ethyl]amino}phenoxyphosphinyl)methoxy]propyl}adenine (compound 16): a method for preparing, in high diastereomeric purity, intermediate compounds 13 and 15: and a method for preparing intermediate compound 12: 9-{(R)-2-[((S)-{[(S)-1-(isopropoxycarbonyl)ethyl]amino}phenoxyphosphinyl)methoxy]propyl}adenine has anti-viral properties.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: May 24, 2016
    Assignee: Gilead Sciences, Inc.
    Inventors: Denise A. Colby, Andrew Anthony Martins, Benjamin James Roberts, Robert William Scott, Nicole S. White
  • Compositions and methods for the treatment of fibromyalgia pain
    Patent number: 9346742
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of fibromyalgia pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, post herpetic neuralgia, diabetic neuropathy, bipolar depression, stress, cancer pain, and lower back pain.
    Type: Grant
    Filed: February 10, 2013
    Date of Patent: May 24, 2016
    Assignee: CELLIX BIO PRIVATE LIMITED
    Inventor: Mahesh Kandula
  • Compositions and methods for treating cancer
    Patent number: 9345705
    Abstract: The instant invention provides a method of treating a cancer, selected from the group consisting of breast cancer, melanoma, colorectal cancer, non-small cell lung cancer and ovarian cancer, by administering a combination of a WEE1 inhibitor and a CHK1 inhibitor, wherein the WEE1 inhibitor is MK-1775 or a pharmaceutically acceptable salt thereof, or MK-3652 or a pharmaceutically acceptable salt thereof, and the CHK1 inhibitor is MK-8776 or a pharmaceutically acceptable salt thereof, or SCH900444 or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 11, 2012
    Date of Patent: May 24, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Stuart Denham Shumway, Carlo Toniatti, Brian Scott Roberts, Melissa M. Martin